AustralieFrV1, PubMed, Checkpoint, bibRecord, 002B98

Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.

Identifieur interne : 002B98 ( PubMed/Checkpoint ); précédent : 002B97; suivant : 002B99

Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.

Auteurs : Antonia Lepida [Belgique] ; Massimo Colombo [Italie] ; Inmaculada Fernandez [Espagne] ; Djamal Abdurakhmanov [Russie] ; Paulo Abrao Ferreira [Brésil] ; Simone I. Strasser [Australie] ; Petr Urbanek [République tchèque] ; Alessandra Mangia [Italie] ; José L. Calleja [Espagne] ; Wafae Iraqi [France] ; Ralph Demasi [États-Unis] ; Isabelle Lonjon-Domanec [France] ; Christophe Moreno [Belgique] ; Heiner Wedemeyer [Allemagne]

Source :

PloS one [ 1932-6203 ] ; 2015.

RBID : pubmed:26398503

Descripteurs français

KwdFr :
- Accessibilité des services de santé, Adulte, Adulte d'âge moyen, Analyse de l'intention de traiter, Analyse multivariée, Anémie (étiologie), Cirrhose du foie (), Cirrhose du foie (physiopathologie), Cirrhose du foie (traitement médicamenteux), Facteurs de risque, Femelle, Foie (), Foie (anatomopathologie), Foie (physiopathologie), Hepacivirus (), Hepacivirus (physiologie), Humains, Hépatite C (), Hépatite C (physiopathologie), Hépatite C (traitement médicamenteux), Hépatite C (virologie), Jeune adulte, Mâle, Oligopeptides (effets indésirables), Oligopeptides (pharmacologie), Oligopeptides (usage thérapeutique), Phénomènes biomécaniques (), Résultat thérapeutique, Sujet âgé.
MESH :
- anatomopathologie : Foie.
- effets indésirables : Oligopeptides.
- pharmacologie : Oligopeptides.
- physiologie : Hepacivirus.
- physiopathologie : Cirrhose du foie, Foie, Hépatite C.
- traitement médicamenteux : Cirrhose du foie, Hépatite C.
- usage thérapeutique : Oligopeptides.
- virologie : Hépatite C.
- étiologie : Anémie.
- Accessibilité des services de santé, Adulte, Adulte d'âge moyen, Analyse de l'intention de traiter, Analyse multivariée, Cirrhose du foie, Facteurs de risque, Femelle, Foie, Hepacivirus, Humains, Hépatite C, Jeune adulte, Mâle, Phénomènes biomécaniques, Résultat thérapeutique, Sujet âgé.

English descriptors

KwdEn :
- Adult, Aged, Anemia (etiology), Biomechanical Phenomena (drug effects), Female, Health Services Accessibility, Hepacivirus (drug effects), Hepacivirus (physiology), Hepatitis C (complications), Hepatitis C (drug therapy), Hepatitis C (physiopathology), Hepatitis C (virology), Humans, Intention to Treat Analysis, Liver (drug effects), Liver (pathology), Liver (physiopathology), Liver Cirrhosis (complications), Liver Cirrhosis (drug therapy), Liver Cirrhosis (physiopathology), Male, Middle Aged, Multivariate Analysis, Oligopeptides (adverse effects), Oligopeptides (pharmacology), Oligopeptides (therapeutic use), Risk Factors, Treatment Outcome, Young Adult.
MESH :
- chemical , adverse effects : Oligopeptides.
- complications : Hepatitis C, Liver Cirrhosis.
- drug effects : Biomechanical Phenomena, Hepacivirus, Liver.
- drug therapy : Hepatitis C, Liver Cirrhosis.
- etiology : Anemia.
- pathology : Liver.
- chemical , pharmacology : Oligopeptides.
- physiology : Hepacivirus.
- physiopathology : Hepatitis C, Liver, Liver Cirrhosis.
- chemical , therapeutic use : Oligopeptides.
- virology : Hepatitis C.
- Adult, Aged, Female, Health Services Accessibility, Humans, Intention to Treat Analysis, Male, Middle Aged, Multivariate Analysis, Risk Factors, Treatment Outcome, Young Adult.

Abstract

Liver stiffness determined by transient elastography is correlated with hepatic fibrosis stage and has high accuracy for detecting severe fibrosis and cirrhosis in chronic hepatitis C patients. We evaluated the clinical value of baseline FibroScan values for the prediction of safety and efficacy of telaprevir-based therapy in patients with advanced fibrosis and cirrhosis in the telaprevir Early Access Program HEP3002.

DOI: 10.1371/journal.pone.0138503
PubMed: 26398503

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002932
to stream PubMed, to step Curation: 002863

Links to Exploration step

pubmed:26398503

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.</title>
<author><name sortKey="Lepida, Antonia" sort="Lepida, Antonia" uniqKey="Lepida A" first="Antonia" last="Lepida">Antonia Lepida</name>
<affiliation wicri:level="3"><nlm:affiliation>Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Colombo, Massimo" sort="Colombo, Massimo" uniqKey="Colombo M" first="Massimo" last="Colombo">Massimo Colombo</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Division of Gastroenterology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita' degli Studi di Milano, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medicine, Division of Gastroenterology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita' degli Studi di Milano, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fernandez, Inmaculada" sort="Fernandez, Inmaculada" uniqKey="Fernandez I" first="Inmaculada" last="Fernandez">Inmaculada Fernandez</name>
<affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario 12 de Octubre, Sección de Aparato Digestivo, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Universitario 12 de Octubre, Sección de Aparato Digestivo, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Abdurakhmanov, Djamal" sort="Abdurakhmanov, Djamal" uniqKey="Abdurakhmanov D" first="Djamal" last="Abdurakhmanov">Djamal Abdurakhmanov</name>
<affiliation wicri:level="3"><nlm:affiliation>I.M. Sechenov First Moscow State Medical University, E.M. Tareev Clinic for Nephrology, Internal and Occupational Medicine, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>I.M. Sechenov First Moscow State Medical University, E.M. Tareev Clinic for Nephrology, Internal and Occupational Medicine, Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferreira, Paulo Abrao" sort="Ferreira, Paulo Abrao" uniqKey="Ferreira P" first="Paulo Abrao" last="Ferreira">Paulo Abrao Ferreira</name>
<affiliation wicri:level="4"><nlm:affiliation>Outpatient Clinic to HIV and Viral Hepatitis Division of Infectious Disease, Federal University of São Paulo, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Outpatient Clinic to HIV and Viral Hepatitis Division of Infectious Disease, Federal University of São Paulo, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Strasser, Simone I" sort="Strasser, Simone I" uniqKey="Strasser S" first="Simone I" last="Strasser">Simone I. Strasser</name>
<affiliation wicri:level="4"><nlm:affiliation>AW Morrow Gastroenterology and Liver Center, Royal Prince Alfred hospital and University of Sydney, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>AW Morrow Gastroenterology and Liver Center, Royal Prince Alfred hospital and University of Sydney, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
<settlement type="city">Sydney</settlement>
</placeName>
<orgName type="university">Université de Sydney</orgName>
</affiliation>
</author>
<author><name sortKey="Urbanek, Petr" sort="Urbanek, Petr" uniqKey="Urbanek P" first="Petr" last="Urbanek">Petr Urbanek</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, First Medical Faculty, Charles University, and Central Military Hospital Prague, Prague, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Department of Internal Medicine, First Medical Faculty, Charles University, and Central Military Hospital Prague, Prague</wicri:regionArea>
<placeName><settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mangia, Alessandra" sort="Mangia, Alessandra" uniqKey="Mangia A" first="Alessandra" last="Mangia">Alessandra Mangia</name>
<affiliation wicri:level="1"><nlm:affiliation>Liver Unit, IRCCS Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Liver Unit, IRCCS Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo</wicri:regionArea>
<wicri:noRegion>San Giovanni Rotondo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calleja, Jose L" sort="Calleja, Jose L" uniqKey="Calleja J" first="José L" last="Calleja">José L. Calleja</name>
<affiliation wicri:level="3"><nlm:affiliation>Gastroenterology, Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, CIBERehd, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Gastroenterology, Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, CIBERehd, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Iraqi, Wafae" sort="Iraqi, Wafae" uniqKey="Iraqi W" first="Wafae" last="Iraqi">Wafae Iraqi</name>
<affiliation wicri:level="3"><nlm:affiliation>Janssen Pharmaceuticals, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Janssen Pharmaceuticals, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Demasi, Ralph" sort="Demasi, Ralph" uniqKey="Demasi R" first="Ralph" last="Demasi">Ralph Demasi</name>
<affiliation wicri:level="2"><nlm:affiliation>Janssen Research and development, Titusville, New Jersey, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research and development, Titusville, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lonjon Domanec, Isabelle" sort="Lonjon Domanec, Isabelle" uniqKey="Lonjon Domanec I" first="Isabelle" last="Lonjon-Domanec">Isabelle Lonjon-Domanec</name>
<affiliation wicri:level="3"><nlm:affiliation>Janssen Pharmaceuticals, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Janssen Pharmaceuticals, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name>
<affiliation wicri:level="3"><nlm:affiliation>Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wedemeyer, Heiner" sort="Wedemeyer, Heiner" uniqKey="Wedemeyer H" first="Heiner" last="Wedemeyer">Heiner Wedemeyer</name>
<affiliation wicri:level="3"><nlm:affiliation>Medizinische Hochschule Hannover, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medizinische Hochschule Hannover, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26398503</idno>
<idno type="pmid">26398503</idno>
<idno type="doi">10.1371/journal.pone.0138503</idno>
<idno type="wicri:Area/PubMed/Corpus">002932</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002932</idno>
<idno type="wicri:Area/PubMed/Curation">002863</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002863</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002863</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002863</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.</title>
<author><name sortKey="Lepida, Antonia" sort="Lepida, Antonia" uniqKey="Lepida A" first="Antonia" last="Lepida">Antonia Lepida</name>
<affiliation wicri:level="3"><nlm:affiliation>Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Colombo, Massimo" sort="Colombo, Massimo" uniqKey="Colombo M" first="Massimo" last="Colombo">Massimo Colombo</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Division of Gastroenterology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita' degli Studi di Milano, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medicine, Division of Gastroenterology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita' degli Studi di Milano, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fernandez, Inmaculada" sort="Fernandez, Inmaculada" uniqKey="Fernandez I" first="Inmaculada" last="Fernandez">Inmaculada Fernandez</name>
<affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario 12 de Octubre, Sección de Aparato Digestivo, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Universitario 12 de Octubre, Sección de Aparato Digestivo, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Abdurakhmanov, Djamal" sort="Abdurakhmanov, Djamal" uniqKey="Abdurakhmanov D" first="Djamal" last="Abdurakhmanov">Djamal Abdurakhmanov</name>
<affiliation wicri:level="3"><nlm:affiliation>I.M. Sechenov First Moscow State Medical University, E.M. Tareev Clinic for Nephrology, Internal and Occupational Medicine, Moscow, Russia.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>I.M. Sechenov First Moscow State Medical University, E.M. Tareev Clinic for Nephrology, Internal and Occupational Medicine, Moscow</wicri:regionArea>
<placeName><settlement type="city">Moscou</settlement>
<region>District fédéral central</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferreira, Paulo Abrao" sort="Ferreira, Paulo Abrao" uniqKey="Ferreira P" first="Paulo Abrao" last="Ferreira">Paulo Abrao Ferreira</name>
<affiliation wicri:level="4"><nlm:affiliation>Outpatient Clinic to HIV and Viral Hepatitis Division of Infectious Disease, Federal University of São Paulo, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Outpatient Clinic to HIV and Viral Hepatitis Division of Infectious Disease, Federal University of São Paulo, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
<settlement type="city">São Paulo</settlement>
</placeName>
<orgName type="university">Université de São Paulo</orgName>
</affiliation>
</author>
<author><name sortKey="Strasser, Simone I" sort="Strasser, Simone I" uniqKey="Strasser S" first="Simone I" last="Strasser">Simone I. Strasser</name>
<affiliation wicri:level="4"><nlm:affiliation>AW Morrow Gastroenterology and Liver Center, Royal Prince Alfred hospital and University of Sydney, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>AW Morrow Gastroenterology and Liver Center, Royal Prince Alfred hospital and University of Sydney, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
<settlement type="city">Sydney</settlement>
</placeName>
<orgName type="university">Université de Sydney</orgName>
</affiliation>
</author>
<author><name sortKey="Urbanek, Petr" sort="Urbanek, Petr" uniqKey="Urbanek P" first="Petr" last="Urbanek">Petr Urbanek</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, First Medical Faculty, Charles University, and Central Military Hospital Prague, Prague, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Department of Internal Medicine, First Medical Faculty, Charles University, and Central Military Hospital Prague, Prague</wicri:regionArea>
<placeName><settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mangia, Alessandra" sort="Mangia, Alessandra" uniqKey="Mangia A" first="Alessandra" last="Mangia">Alessandra Mangia</name>
<affiliation wicri:level="1"><nlm:affiliation>Liver Unit, IRCCS Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Liver Unit, IRCCS Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo</wicri:regionArea>
<wicri:noRegion>San Giovanni Rotondo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calleja, Jose L" sort="Calleja, Jose L" uniqKey="Calleja J" first="José L" last="Calleja">José L. Calleja</name>
<affiliation wicri:level="3"><nlm:affiliation>Gastroenterology, Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, CIBERehd, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Gastroenterology, Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, CIBERehd, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Iraqi, Wafae" sort="Iraqi, Wafae" uniqKey="Iraqi W" first="Wafae" last="Iraqi">Wafae Iraqi</name>
<affiliation wicri:level="3"><nlm:affiliation>Janssen Pharmaceuticals, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Janssen Pharmaceuticals, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Demasi, Ralph" sort="Demasi, Ralph" uniqKey="Demasi R" first="Ralph" last="Demasi">Ralph Demasi</name>
<affiliation wicri:level="2"><nlm:affiliation>Janssen Research and development, Titusville, New Jersey, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research and development, Titusville, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lonjon Domanec, Isabelle" sort="Lonjon Domanec, Isabelle" uniqKey="Lonjon Domanec I" first="Isabelle" last="Lonjon-Domanec">Isabelle Lonjon-Domanec</name>
<affiliation wicri:level="3"><nlm:affiliation>Janssen Pharmaceuticals, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Janssen Pharmaceuticals, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name>
<affiliation wicri:level="3"><nlm:affiliation>Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wedemeyer, Heiner" sort="Wedemeyer, Heiner" uniqKey="Wedemeyer H" first="Heiner" last="Wedemeyer">Heiner Wedemeyer</name>
<affiliation wicri:level="3"><nlm:affiliation>Medizinische Hochschule Hannover, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medizinische Hochschule Hannover, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Anemia (etiology)</term>
<term>Biomechanical Phenomena (drug effects)</term>
<term>Female</term>
<term>Health Services Accessibility</term>
<term>Hepacivirus (drug effects)</term>
<term>Hepacivirus (physiology)</term>
<term>Hepatitis C (complications)</term>
<term>Hepatitis C (drug therapy)</term>
<term>Hepatitis C (physiopathology)</term>
<term>Hepatitis C (virology)</term>
<term>Humans</term>
<term>Intention to Treat Analysis</term>
<term>Liver (drug effects)</term>
<term>Liver (pathology)</term>
<term>Liver (physiopathology)</term>
<term>Liver Cirrhosis (complications)</term>
<term>Liver Cirrhosis (drug therapy)</term>
<term>Liver Cirrhosis (physiopathology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multivariate Analysis</term>
<term>Oligopeptides (adverse effects)</term>
<term>Oligopeptides (pharmacology)</term>
<term>Oligopeptides (therapeutic use)</term>
<term>Risk Factors</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Accessibilité des services de santé</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de l'intention de traiter</term>
<term>Analyse multivariée</term>
<term>Anémie (étiologie)</term>
<term>Cirrhose du foie ()</term>
<term>Cirrhose du foie (physiopathologie)</term>
<term>Cirrhose du foie (traitement médicamenteux)</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Foie ()</term>
<term>Foie (anatomopathologie)</term>
<term>Foie (physiopathologie)</term>
<term>Hepacivirus ()</term>
<term>Hepacivirus (physiologie)</term>
<term>Humains</term>
<term>Hépatite C ()</term>
<term>Hépatite C (physiopathologie)</term>
<term>Hépatite C (traitement médicamenteux)</term>
<term>Hépatite C (virologie)</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Oligopeptides (effets indésirables)</term>
<term>Oligopeptides (pharmacologie)</term>
<term>Oligopeptides (usage thérapeutique)</term>
<term>Phénomènes biomécaniques ()</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Foie</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Hepatitis C</term>
<term>Liver Cirrhosis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Biomechanical Phenomena</term>
<term>Hepacivirus</term>
<term>Liver</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C</term>
<term>Liver Cirrhosis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Anemia</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Liver</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Hepacivirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Hepacivirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Cirrhose du foie</term>
<term>Foie</term>
<term>Hépatite C</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hepatitis C</term>
<term>Liver</term>
<term>Liver Cirrhosis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Cirrhose du foie</term>
<term>Hépatite C</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Hépatite C</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hepatitis C</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Anémie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Health Services Accessibility</term>
<term>Humans</term>
<term>Intention to Treat Analysis</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multivariate Analysis</term>
<term>Risk Factors</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Accessibilité des services de santé</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de l'intention de traiter</term>
<term>Analyse multivariée</term>
<term>Cirrhose du foie</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Foie</term>
<term>Hepacivirus</term>
<term>Humains</term>
<term>Hépatite C</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Phénomènes biomécaniques</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Liver stiffness determined by transient elastography is correlated with hepatic fibrosis stage and has high accuracy for detecting severe fibrosis and cirrhosis in chronic hepatitis C patients. We evaluated the clinical value of baseline FibroScan values for the prediction of safety and efficacy of telaprevir-based therapy in patients with advanced fibrosis and cirrhosis in the telaprevir Early Access Program HEP3002.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26398503</PMID>
<DateCreated><Year>2015</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>05</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>10</Volume>
<Issue>9</Issue>
<PubDate><Year>2015</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.</ArticleTitle>
<Pagination><MedlinePgn>e0138503</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0138503</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Liver stiffness determined by transient elastography is correlated with hepatic fibrosis stage and has high accuracy for detecting severe fibrosis and cirrhosis in chronic hepatitis C patients. We evaluated the clinical value of baseline FibroScan values for the prediction of safety and efficacy of telaprevir-based therapy in patients with advanced fibrosis and cirrhosis in the telaprevir Early Access Program HEP3002.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">1,772 patients with HCV-1 and bridging fibrosis or cirrhosis were treated with telaprevir plus pegylated interferon-α and ribavirin (PR) for 12 weeks followed by PR alone, the total treatment duration depending on virological response and previous response type. Liver fibrosis stage was determined either by liver biopsy or by non-invasive markers. 1,282 patients (72%) had disease stage assessed by FibroScan; among those 46% were classified as Metavir F3 at baseline and 54% as F4.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 1,139 patients (64%) achieved a sustained virological response (SVR) by intention-to-treat analysis. Baseline FibroScan values were tested for association with SVR and the occurrence of adverse events. By univariate analysis, higher baseline FibroScan values were predictive of lower sustained virological response rates and treatment-related anemia. By multivariate analysis, FibroScan was no longer statistically significant as an independent predictor, but higher FibroScan values were correlated with the occurrence of infections and serious adverse events.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">FibroScan has a limited utility as a predictor of safety and efficacy in patients treated with telaprevir-based triple therapy. Nevertheless it can be used in association with other clinical and biological parameters to help determine patients who will benefit from the triple regiments.</AbstractText>
<AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT01508286.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lepida</LastName>
<ForeName>Antonia</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Colombo</LastName>
<ForeName>Massimo</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Division of Gastroenterology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universita' degli Studi di Milano, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fernandez</LastName>
<ForeName>Inmaculada</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Hospital Universitario 12 de Octubre, Sección de Aparato Digestivo, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Abdurakhmanov</LastName>
<ForeName>Djamal</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University, E.M. Tareev Clinic for Nephrology, Internal and Occupational Medicine, Moscow, Russia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ferreira</LastName>
<ForeName>Paulo Abrao</ForeName>
<Initials>PA</Initials>
<AffiliationInfo><Affiliation>Outpatient Clinic to HIV and Viral Hepatitis Division of Infectious Disease, Federal University of São Paulo, São Paulo, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Strasser</LastName>
<ForeName>Simone I</ForeName>
<Initials>SI</Initials>
<AffiliationInfo><Affiliation>AW Morrow Gastroenterology and Liver Center, Royal Prince Alfred hospital and University of Sydney, Sydney, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Urbanek</LastName>
<ForeName>Petr</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Internal Medicine, First Medical Faculty, Charles University, and Central Military Hospital Prague, Prague, Czech Republic.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mangia</LastName>
<ForeName>Alessandra</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Liver Unit, IRCCS Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Calleja</LastName>
<ForeName>José L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo><Affiliation>Gastroenterology, Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, CIBERehd, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Iraqi</LastName>
<ForeName>Wafae</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Janssen Pharmaceuticals, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>DeMasi</LastName>
<ForeName>Ralph</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Janssen Research and development, Titusville, New Jersey, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lonjon-Domanec</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Janssen Pharmaceuticals, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moreno</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wedemeyer</LastName>
<ForeName>Heiner</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Medizinische Hochschule Hannover, Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT01508286</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>09</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>655M5O3W0U</RegistryNumber>
<NameOfSubstance UI="C486464">telaprevir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2010 Oct;65(10):2204-11</RefSource>
<PMID Version="1">20656678</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2012 Dec 26;308(24):2584-93</RefSource>
<PMID Version="1">23268517</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2006 Mar;55(3):403-8</RefSource>
<PMID Version="1">16020491</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2007 May;45(5):1290-7</RefSource>
<PMID Version="1">17464971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aliment Pharmacol Ther. 2014 May;39(10):1213-24</RefSource>
<PMID Version="1">24654657</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2009 Feb;16(2):132-40</RefSource>
<PMID Version="1">19175875</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Liver Dis. 2006 Nov;10(4):919-40</RefSource>
<PMID Version="1">17164125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2005 Feb;128(2):343-50</RefSource>
<PMID Version="1">15685546</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Gastroenterol. 2014;14:87</RefSource>
<PMID Version="1">24884400</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Chem. 2006 Oct;52(10):1887-96</RefSource>
<PMID Version="1">16931569</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2006 Dec;44(6):1511-7</RefSource>
<PMID Version="1">17133503</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2014 May;21(5):333-40</RefSource>
<PMID Version="1">24716636</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Gastroenterol. 2011 Nov 7;17(41):4581-9</RefSource>
<PMID Version="1">22147963</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2013 Sep;59(3):434-41</RefSource>
<PMID Version="1">23669289</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gastroenterol Hepatol. 2010 May;25(5):964-9</RefSource>
<PMID Version="1">20546451</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterol Hepatol (N Y). 2011 Jul;7(7):445-54</RefSource>
<PMID Version="1">22298979</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Gastroenterol Hepatol. 2011 Jun;9(6):509-516.e1</RefSource>
<PMID Version="1">21397729</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Hepatol. 2014 Sep 27;6(9):660-9</RefSource>
<PMID Version="1">25276282</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2011 Jun;140(7):1970-9, 1979.e1-3</RefSource>
<PMID Version="1">21376047</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2011 Nov;55(5):1017-24</RefSource>
<PMID Version="1">21354450</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2013 Mar;58(3):479-87</RefSource>
<PMID Version="1">23183529</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antiviral Res. 2009 Aug;83(2):127-34</RefSource>
<PMID Version="1">19443053</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2014 Feb;34 Suppl 1:38-45</RefSource>
<PMID Version="1">24373077</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2013 Oct;59(4):675-83</RefSource>
<PMID Version="1">23712051</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2014 Nov;61(5):976-83</RefSource>
<PMID Version="1">24946280</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2010 Sep;52(3):833-44</RefSource>
<PMID Version="1">20564351</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatol Res. 2010 Apr;40(4):383-92</RefSource>
<PMID Version="1">20236358</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Gastroenterol. 2007;7:40</RefSource>
<PMID Version="1">17937811</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2014 Feb;60(2):392-420</RefSource>
<PMID Version="1">24331294</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Gastroenterol. 2013 Mar 28;19(12):1890-900</RefSource>
<PMID Version="1">23569334</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Mar 31;364(13):1207-17</RefSource>
<PMID Version="1">21449784</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2008 May;48(5):835-47</RefSource>
<PMID Version="1">18334275</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(2):e55285</RefSource>
<PMID Version="1">23383319</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gut. 2014 Jul;63(7):1150-8</RefSource>
<PMID Version="1">24201995</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aliment Pharmacol Ther. 2014 Jan;39(1):93-103</RefSource>
<PMID Version="1">24206566</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Can J Gastroenterol. 2013 Mar;27(3):149-58</RefSource>
<PMID Version="1">23516679</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Jun 23;364(25):2429-38</RefSource>
<PMID Version="1">21696309</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Mar 31;364(13):1195-206</RefSource>
<PMID Version="1">21449783</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2012 Sep;57(3):541-8</RefSource>
<PMID Version="1">22612998</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Jun 23;364(25):2417-28</RefSource>
<PMID Version="1">21696308</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2014 Jan;59(1):46-8</RefSource>
<PMID Version="1">23813604</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2013 Jun 4;158(11):807-20</RefSource>
<PMID Version="1">23732714</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Jun 23;364(25):2405-16</RefSource>
<PMID Version="1">21696307</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Liver Int. 2012 Feb;32 Suppl 1:113-9</RefSource>
<PMID Version="1">22212581</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(10):e47715</RefSource>
<PMID Version="1">23082200</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aliment Pharmacol Ther. 2011 Sep;34(6):656-63</RefSource>
<PMID Version="1">21752038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Rev Esp Enferm Dig. 2010 Jul;102(7):426-34</RefSource>
<PMID Version="1">20617863</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hepatol. 2011 Apr;54(4):650-9</RefSource>
<PMID Version="1">21146892</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2012 Feb;19(2):e184-93</RefSource>
<PMID Version="1">22239518</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2010;15(4):617-31</RefSource>
<PMID Version="1">20587855</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dig Liver Dis. 2013 Oct;45(10):840-3</RefSource>
<PMID Version="1">23660078</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000740" MajorTopicYN="N">Anemia</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001696" MajorTopicYN="N">Biomechanical Phenomena</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4580464</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>05</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>08</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>5</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26398503</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0138503</ArticleId>
<ArticleId IdType="pii">PONE-D-15-16106</ArticleId>
<ArticleId IdType="pmc">PMC4580464</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Belgique</li>
<li>Brésil</li>
<li>Espagne</li>
<li>France</li>
<li>Italie</li>
<li>Russie</li>
<li>République tchèque</li>
<li>États-Unis</li>
</country>
<region><li>Basse-Saxe</li>
<li>Bohême centrale</li>
<li>Communauté de Madrid</li>
<li>District fédéral central</li>
<li>Lombardie</li>
<li>New Jersey</li>
<li>Nouvelle-Galles du Sud</li>
<li>Région de Bruxelles-Capitale</li>
<li>État de São Paulo</li>
<li>Île-de-France</li>
</region>
<settlement><li>Bruxelles</li>
<li>Hanovre</li>
<li>Madrid</li>
<li>Milan</li>
<li>Moscou</li>
<li>Paris</li>
<li>Prague</li>
<li>Sydney</li>
<li>São Paulo</li>
</settlement>
<orgName><li>Université de Sydney</li>
<li>Université de São Paulo</li>
</orgName>
</list>
<tree><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Lepida, Antonia" sort="Lepida, Antonia" uniqKey="Lepida A" first="Antonia" last="Lepida">Antonia Lepida</name>
</region>
<name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name>
</country>
<country name="Italie"><region name="Lombardie"><name sortKey="Colombo, Massimo" sort="Colombo, Massimo" uniqKey="Colombo M" first="Massimo" last="Colombo">Massimo Colombo</name>
</region>
<name sortKey="Mangia, Alessandra" sort="Mangia, Alessandra" uniqKey="Mangia A" first="Alessandra" last="Mangia">Alessandra Mangia</name>
</country>
<country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Fernandez, Inmaculada" sort="Fernandez, Inmaculada" uniqKey="Fernandez I" first="Inmaculada" last="Fernandez">Inmaculada Fernandez</name>
</region>
<name sortKey="Calleja, Jose L" sort="Calleja, Jose L" uniqKey="Calleja J" first="José L" last="Calleja">José L. Calleja</name>
</country>
<country name="Russie"><region name="District fédéral central"><name sortKey="Abdurakhmanov, Djamal" sort="Abdurakhmanov, Djamal" uniqKey="Abdurakhmanov D" first="Djamal" last="Abdurakhmanov">Djamal Abdurakhmanov</name>
</region>
</country>
<country name="Brésil"><region name="État de São Paulo"><name sortKey="Ferreira, Paulo Abrao" sort="Ferreira, Paulo Abrao" uniqKey="Ferreira P" first="Paulo Abrao" last="Ferreira">Paulo Abrao Ferreira</name>
</region>
</country>
<country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Strasser, Simone I" sort="Strasser, Simone I" uniqKey="Strasser S" first="Simone I" last="Strasser">Simone I. Strasser</name>
</region>
</country>
<country name="République tchèque"><region name="Bohême centrale"><name sortKey="Urbanek, Petr" sort="Urbanek, Petr" uniqKey="Urbanek P" first="Petr" last="Urbanek">Petr Urbanek</name>
</region>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Iraqi, Wafae" sort="Iraqi, Wafae" uniqKey="Iraqi W" first="Wafae" last="Iraqi">Wafae Iraqi</name>
</region>
<name sortKey="Lonjon Domanec, Isabelle" sort="Lonjon Domanec, Isabelle" uniqKey="Lonjon Domanec I" first="Isabelle" last="Lonjon-Domanec">Isabelle Lonjon-Domanec</name>
</country>
<country name="États-Unis"><region name="New Jersey"><name sortKey="Demasi, Ralph" sort="Demasi, Ralph" uniqKey="Demasi R" first="Ralph" last="Demasi">Ralph Demasi</name>
</region>
</country>
<country name="Allemagne"><region name="Basse-Saxe"><name sortKey="Wedemeyer, Heiner" sort="Wedemeyer, Heiner" uniqKey="Wedemeyer H" first="Heiner" last="Wedemeyer">Heiner Wedemeyer</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B98 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002B98 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:26398503
   |texte=   Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:26398503" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.

Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki